Joseph Palumbo
Overview
Explore the profile of Joseph Palumbo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haroon J, Jordan K, Mahdavi K, Rindner E, Becerra S, Surya J, et al.
Medicine (Baltimore)
. 2024 Jul;
103(30):e39027.
PMID: 39058809
Background: Alzheimer's disease (AD) is a progressive, multifactorial, neurodegenerative disorder affecting >6 million Americans. Chronic, low-grade neuroinflammation, and insulin resistance may drive AD pathogenesis. We explored the neurophysiological and neuropsychological...
2.
Markham P, Bajaj J, Thuluvath P, Koch D, Palumbo J
J Hepatol
. 2024 Feb;
81(2):e71-e73.
PMID: 38403026
No abstract available.
3.
Francisco B, Sharma B, Russell H, Rosenfeldt L, Owens A, Flick M, et al.
Blood Adv
. 2022 Jul;
6(14):4297-4300.
PMID: 35877135
No abstract available.
4.
Connor P, Sanchez van Kammen M, Lensing A, Chalmers E, Kallay K, Hege K, et al.
Blood Adv
. 2020 Dec;
4(24):6250-6258.
PMID: 33351120
Anticoagulant treatment of pediatric cerebral venous thrombosis has not been evaluated in randomized trials. We evaluated the safety and efficacy of rivaroxaban and standard anticoagulants in the predefined subgroup of...
5.
Girnius A, Zentner D, Valente A, Pieper P, Economy K, Ladouceur M, et al.
Heart
. 2020 Nov;
107(17):1390-1397.
PMID: 33234672
Background/objectives: Pregnancy may potentiate the inherent hypercoagulability of the Fontan circulation, thereby amplifying adverse events. This study sought to evaluate thrombosis and bleeding risk in pregnant women with a Fontan....
6.
Cavaleri M, Veroux M, Palermo F, Vasile F, Mineri M, Palumbo J, et al.
J Clin Med
. 2019 Jan;
8(1).
PMID: 30642015
Background: Kidney transplantation is considered the first-choice therapy in end-stage renal disease (ESRD) patients. Despite recent improvements in terms of outcomes and graft survival in recipients, postoperative complications still concern...
7.
Chan A, Lensing A, Kubitza D, Brown G, Elorza D, Ybarra M, et al.
Thromb J
. 2018 Nov;
16:29.
PMID: 30410424
Background: Venous thromboembolism (VTE) in young children is not well documented. Methods: Clinicians from 12 institutions retrospectively evaluated the presentation, therapeutic management, and outcome of VTE in children younger than...
8.
Justice L, Nelson D, Palumbo J, Sawyer J, Patel M, Byrnes J
Cardiol Young
. 2017 Sep;
28(2):214-221.
PMID: 28889818
Objective: Reports in the literature of treatment with recombinant tissue plasminogen activator following cardiac surgery are limited. We reviewed our experience to provide a case series of the therapeutic use...
9.
Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis
Takei K, Tsuda K, Takahashi F, Palumbo J
Amyotroph Lateral Scler Frontotemporal Degener
. 2017 Sep;
18(sup1):64-70.
PMID: 28872916
Study MCI186-19 investigated the safety and efficacy of edaravone in the treatment of ALS. The 24-week, double-blind period was followed by a 24-week, open-label, active extension period. Patients originally receiving...
10.
Takahashi F, Takei K, Tsuda K, Palumbo J
Amyotroph Lateral Scler Frontotemporal Degener
. 2017 Sep;
18(sup1):32-39.
PMID: 28872914
In the 24-week double-blind study of edaravone in ALS (MCI186-16), edaravone did not show a statistically significant difference versus placebo for the primary efficacy endpoint. For post-hoc analyses, two subpopulations...